Dovitinib (lactate)

Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively[1].

Product Specifications

CAS Number

[692737-80-7]

Product Name Alternative

CHIR-258 lactate; TKI-258 lactate

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

C-Kit; FGFR; FLT3; PDGFR; VEGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Dovitinib-lactate.html

Purity

99.75

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

O=C(N1)C(C(NC2=C3)=NC2=CC=C3N4CCN(C)CC4)=C(N)C5=C1C=CC=C5F.O=C(O)C(C)O

Molecular Formula

C24H27FN6O4

Molecular Weight

482.51

Precautions

H302, H315, H319, H335

References & Citations

[1]Trudel S, et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t (4;14) multiple myeloma. Blood. 2005, 105 (7), 2941-2948.|[2]Huynh H, et al. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. J Hepatol. 2012, 56 (3), 595-601.